

AMIR H. NASHAT
General Partner
Boston

Amir H. Nashat is a general partner in our Boston office. Amir joined Polaris in April 2002 and focuses on investments in the life sciences.

Experience:

Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. During his time at MIT, Amir completed an internship in the London office of Goldman, Sachs & Company.

Boards:

Amir currently represents Polaris as a Director of [Athenix Corporation](#), [aTyr Pharmaceuticals](#), [Avila Therapeutics](#), [Bind Biosciences](#), [Fate Therapeutics](#), Living Proof, [Pervasis Therapeutics](#), [Promedior Pharmaceuticals](#), Selecta Biosciences and [WaveRx](#). Amir played an instrumental role in the inception of Living Proof (then named Andora), and [Pervasis](#), serving as the founding President of both companies. Additionally, Amir has served as a Director of [Adnexus Therapeutics](#) (acquired by Bristol Myers Squibb) and Hydra Biosciences, and as an Observer of [GI Dynamics](#) and [Advion](#).

Amir currently serves on the Board of the New England Venture Capital Association, on the Advisory Board of the [Simmons School of Management Entrepreneurship Initiative](#), and is a [Deshpande Center for Technological Innovation](#) at MIT.

Education:

Prior to obtaining his PhD at MIT, Amir earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.